July 11, 2019 - "Strong fundamentals fueling business development and pipeline progress"
AUGUST 21, 2019 - Orexo will together with its partner GAIA AG develop and commercialize a new digital therapy to increase access and improve treatments of Opioid Use Disorder. Why digital therapies, why now and why together with GAIA? Nikolaj Sørensen, CEO, answers this questions in the latest version of Orexo Our View.
AUGUST 20, 2019 – Orexo has entered into an exclusive agreement with GAIA AG, a global leader in digital therapeutics, to develop a digital therapy for the treatment of Opioid Use Disorder. According to the agreement Orexo will have the exclusive global commercial rights to the product and intends to launch it in the US in 2022, subject to regulatory approval.
JULY 11, 2019 – Zubsolv® remains the core driver of Orexo’s strong financial performance and record profitability. With a cash position of SEK 697 million and continued traction in the US, we remain focused on expanding our pipeline and product portfolio with commercially attractive assets to drive future growth.
JULY 10, 2019 – Today Orexo announces that an agreement have been signed for Zubsolv® in Australia and New Zealand with Mundipharma Australia, who has worked closely with Orexo in the approval process. Orexo will receive double-digit royalty on net sales and the launch in Australia will be initiated early next year.